"Solismaa, Anssi" - Selaus tekijän mukaan TUNICRIS-julkaisut

    • Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels 

      Rask, Susanna Maria; Lamminmäki, Miina; Kampman, Olli; Hämäläinen, Mari; Moilanen, Eeva; Seppälä, Niko; Solismaa, Anssi (2026)
      article
      Aims: Clozapine is the most effective antipsychotic in treatment-resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio ...
    • Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports 

      Hahl-Häkkinen, Lydia; Rask, Susanna Maria; Solismaa, Anssi; Ruuhonen, Sanna; Leinonen, Esa (2023)
      article
      Background: Alcohol use disorder (AUD) is a significant co-morbidity in patients with schizophrenia. Clozapine offers some benefits in treating patients with refractory schizophrenia and AUD, but co-medicating with disulfiram ...
    • Genetic Risk Scores Associated with Temperament Clusters in Finnish Depression Patients 

      Salminen, Simo-Pekko; Solismaa, Anssi; Lyytikäinen, Leo-Pekka; Paavonen, Vesa; Mononen, Nina; Lehtimäki, Terho; Leinonen, Esa; Kampman, Olli (2023)
      article
      Objective: Cloninger's temperament dimensions have been studied widely in relation to genetics. In this study, we examined Cloninger's temperament dimensions grouped with cluster analyses and their association with single ...
    • Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine 

      Klemettilä, Jari Pekka; Solismaa, Anssi; Seppälä, Niko; Hämäläinen, Mari; Moilanen, Eeva; Leinonen, Esa; Kampman, Olli (12 / 2021)
      article
      Metabolic syndrome and related cardiovascular risk factors are well-known comorbidities among patients with schizophrenia. Biomarkers of these antipsychotic-associated metabolic adverse effects and antipsychotic-induced ...
    • IL-8 and IL-1RA serum levels predicting depression treatment response in 6-week follow-up 

      Mökkönen, Tuukka; Solismaa, Anssi; Hämäläinen, Mari; Moilanen, Eeva; Kampman, Olli (2025)
      article
      Objective: This study aims to ascertain the effect of baseline IL-1Ra and IL-8 in the treatment response of patients with major depressive disorder (MDD) and to clarify the relationship between inflammation markers and ...
    • Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users 

      Hietala, Elina; Solismaa, Anssi; Lähteenvuo, Markku; Ahola-Olli, Ari V.; Häkkinen, Katja; Suokas, Kimmo; Isometsä, Erkki; Suvisaari, Jaana; Kieseppä, Tuula; Holm, Minna; Tiihonen, Jari; Lönnqvist, Jouko; Hietala, Jarmo; Wegelius, Asko; Lahdensuo, Kaisla; Haaki, Willehard; Kampman, Olli; Palotie, Aarno; Kyttälä, Aija; Kämpe, Anders; Tuulio-Henriksson, Annamari; Toivola, Auli; Neale, Benjamin; Shen, Huei Yi; Västrik, Imre; Veijola, Juha; Niemi-Pynttäri, Jussi; Daly, Mark; Ristiluoma, Noora; Pietiläinen, Olli; Kajanne, Risto; Hyman, Steven E.; Singh, Tarjinder; Männynsalo, Teemu; Paunio, Tiina; Jukuri, Tuomas (2025)
      article
      Background: Non-adherence and negative attitudes towards medication are major problems in treating psychotic disorders. Cytochrome P450 2D6 (CYP2D6) contributes to the metabolism of aripiprazole and risperidone. Variations ...
    • Leptin and leptin receptor gene polymorphisms and depression treatment response 

      Tavast, Ida-Maria; Solismaa, Anssi; Lyytikäinen, Leo Pekka; Mononen, Nina; Moilanen, Eeva; Hämäläinen, Mari; Lehtimäki, Terho; Kampman, Olli (2024)
      article
      Objective: Associations between leptin (LEP) and leptin receptor (LEPR) gene polymorphisms and mood disorders have been found but not yet confirmed in multiple studies. The aim of our study was to study the associations ...
    • Meta-analyses of clozapine, norclozapine levels and their ratio across three genome wide association studies 

      Rask, Susanna Maria; Solismaa, Anssi; Ahola-Olli, Ari; Molden, Espen; O’Connell, Kevin Sean; Lyytikäinen, Leo Pekka; Mononen, Nina; Lehtimäki, Terho; Kampman, Olli (2025)
      article
      Recent genome wide association studies (GWAS) found associations between clozapine serum levels and single nucleotide polymorphisms (SNP) in intragenic region between cytochrome P450 1A1 (CYP1A1) and CYP1A2 and nuclear ...
    • Polymorphisms in ERBB4 and TACR1 associated with dry mouth in clozapine-treated patients 

      Puolakka, Hanna; Solismaa, Anssi; Lyytikäinen, Leo Pekka; Viikki, Merja; Seppälä, Niko; Mononen, Nina; Lehtimäki, Terho; Kampman, Olli (04 / 2024)
      article
      Objective: Sialorrhea is a common and uncomfortable adverse effect of clozapine, and its severity varies between patients. The aim of the study was to select broadly genes related to the regulation of salivation and study ...
    • Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder 

      Lähteenvuo, Markku; Tiihonen, Jari; Solismaa, Anssi; Tanskanen, Antti; Mittendorfer-Rutz, Ellenor; Taipale, Heidi (13.01.2024)
      article
      Importance: Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption. Objective: To test whether the risk of hospitalization ...